ERBB2 and neoplasm: More recently, further HER2-targeted therapies have been developed, such as bispecific antibodies, drug-conjugated antibodies (ADCs), and Tyrosine Kinase Inhibitors (TKIs) [4,5] which, despite their anti-tumor efficacy, can give rise to toxicity and impact patients’ quality of life.